Evidence map›Paper›PMID 34003775›Full record

ArticleCancer research2021

The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.

Prashant V Bommi, Charles M Bowen, Laura Reyes-Uribe, Wenhui Wu, Hiroyuki Katayama, Pedro Rocha, Edwin R Parra, Alejandro Francisco-Cruz, Zuhal Ozcan, Elena Tosti and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Prashant V BommiDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9457-1730
Charles M BowenDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5400-4304
Laura Reyes-UribeDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wenhui WuDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hiroyuki KatayamaDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3117-1390
Pedro RochaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9068-1636
Alejandro Francisco-CruzDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1558-8084
Zuhal OzcanDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8693-1935
Elena TostiDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.
Jason A WillisDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8238-8552
Hong WuDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Melissa W TaggartDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7803-9904
Jared K BurksDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6173-9074
Patrick M LynchDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Winfried EdelmannDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.
Paul A ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Krishna M SinhaDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samir M HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eduardo VilarDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. EVilar@mdanderson.org.ORCID 0000-0001-6404-3761
The University of Texas MD Anderson Cancer Center · USAlbert Einstein College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
Analyzing the Hypersensitivity of MMR-deficient Colorectal Cancers to mTOR Inhibition and the Response of Cancer Stem CellsR01CA248536 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI EDELMANN, WINFRIED · 2021 to 2025
$2.0M
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch SyndromeR01CA219463 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILAR SANCHEZ, EDUARDO · 2017 to 2021
$1.6M
Single Cell Spatial Analysis in TissueR50CA243707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BURKS, JARED KYLE · 2020 to 2024
$1.3M
NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA219463NCI NIH HHS R01 CA248536NCI NIH HHS R50 CA243707NCI NIH HHS T32 CA009666
6 · The paper itself

Abstract

Lynch syndrome is the most common cause of hereditary colorectal cancer and is secondary to germline alterations in one of four DNA mismatch repair (MMR) genes. Here we aimed to provide novel insights into the initiation of MMR-deficient (MMRd) colorectal carcinogenesis by characterizing the expression profile of MMRd intestinal stem cells (ISC). A tissue-specific MMRd mouse model (Villin-Cre;Msh2

Indexed as

DNA Mismatch RepairGene Expression Regulation, NeoplasticTranscriptomeAnimalsApoptosisCarcinogenesisCell ProliferationColorectal Neoplasms, Hereditary NonpolyposisHumansIntestinesMiceMice, Inbred C57BLMice, KnockoutMutS Homolog 2 ProteinPrognosisProteomeLgr5 protein, mouseMsh2 protein, mouseMutS Homolog 2 ProteinProteomeReceptors, G-Protein-Coupled

Identifiers

PMID34003775
PMCPMC8318201
OpenAlexW3139451574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.